Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Urología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
INTERVENTIONAL
Inicio: 1 de feb de 2008
ID: NCT00625664
Reclutando
Fase 2
ClinicalTrials.gov
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC)
INTERVENTIONAL
Inicio: 26 de mar de 2026
ID: NCT07293351
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
INTERVENTIONAL
Inicio: 26 de nov de 2014
ID: NCT02257736
Reclutando
ClinicalTrials.gov
Baseline Ventilatory Parameters in Patients With Acute Neurological Injury
OBSERVATIONAL
Inicio: 1 de may de 2024
ID: NCT06192342
Completado
Fase 1
ClinicalTrials.gov
A Phase 1 Study to Compare Bempegaldesleukin Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (mRCC) (PIVOT IO 011)
INTERVENTIONAL
Inicio: 11 de sept de 2020
ID: NCT04540705
Completado
Fase 3
ClinicalTrials.gov
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
INTERVENTIONAL
Inicio: 1 de oct de 2008
ID: NCT00744497
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Double-blind, Placebo-controlled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy
INTERVENTIONAL
Inicio: 12 de jul de 2024
ID: NCT06290128
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
INTERVENTIONAL
Inicio: 11 de jun de 2019
ID: NCT03767244
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer
INTERVENTIONAL
Inicio: 25 de ene de 2019
ID: NCT03748641
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
INTERVENTIONAL
Inicio: 28 de ago de 2017
ID: NCT03207867
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
INTERVENTIONAL
Inicio: 1 de may de 2009
ID: NCT00861614
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer
INTERVENTIONAL
Inicio: 1 de ago de 2007
ID: NCT00519285
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)
INTERVENTIONAL
Inicio: 12 de feb de 2013
ID: NCT01715285
Desconocido
ClinicalTrials.gov
Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Cohort
OBSERVATIONAL
Inicio: 1 de jun de 2019
ID: NCT04534647
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR-214), Versus Nivolumab Alone Versus Standard of Care in Participants With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible
INTERVENTIONAL
Inicio: 5 de feb de 2020
ID: NCT04209114
Completado
ClinicalTrials.gov
Prevalence of Homologous Recombination Repair (HRR) Gene Mutations in Patients With Metastatic Castration-resistant Prostate Cancer in Latin America: PROSPECT Study.
OBSERVATIONAL
Inicio: 21 de abr de 2021
ID: NCT04962880
Completado
ClinicalTrials.gov
Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation
OBSERVATIONAL
Inicio: 20 de ago de 2014
ID: NCT02141438
Aún no recluta
ClinicalTrials.gov
The Amper Study: Amniotic Membrane for the Prevention of Mesh Exposure in Vaginal Reconstructive Surgery
INTERVENTIONAL
Inicio: 1 de mar de 2026
ID: NCT07414849
Completado
ClinicalTrials.gov
Rolandic Epilepsy Genomewide Association International Study
OBSERVATIONAL
Inicio: 1 de jun de 2018
ID: NCT03547050
Terminado
Fase 3
ClinicalTrials.gov
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
INTERVENTIONAL
Inicio: 20 de sept de 2019
ID: NCT04066491
Anterior
1
...
14
15
16
...
434
Siguiente
Filtros